DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted radiation attack on deadly brain tumors begins human testing
Disease control Recruiting nowThis early-stage study is testing whether a radioactive drug called Lutetium-177-PSMA-617 is safe for people with aggressive types of brain cancer called gliomas. The treatment uses a molecule that seeks out and delivers radiation directly to tumor cells that have a specific mark…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for kids with aggressive brain tumors: experimental drug trial opens
Disease control Recruiting nowThis early-stage trial is testing a new drug called CBL0137 in children and young adults (ages 1-21) whose solid tumors, brain tumors, or lymphoma have come back or stopped responding to standard treatments. The main goals are to find the safest dose and see if the drug can help …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC